Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 1, 2010, Pages 85-90

  Drappatz, Jan ^a,c,d   Norden, Andrew D ^a,c,d   Wong, Eric T ^d,e   Doherty, Lisa M ^a   Lafrankie, Debra C ^a   Ciampa, Abigail ^a   Kesari, Santosh ^a,c,d   Sceppa, Christine ^a   Gerard, Mary ^a   Phan, Phuong ^a   Schiff, David ^f   Batchelor, Tracy T ^d,g   Ligon, Keith L ^b,d   Young, Geoffrey ^b,d   Muzikansky, Alona ^c,d   Weiss, Stephanie E ^b,d   Wen, Patrick Y ^a,c,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Glioblastoma; radiotherapy; temozolomide; vandetanib

Indexed keywords

ANGIOGENESIS; ANTIEPILEPTIC DRUGS; DOSE ESCALATION; DOSE LIMITING TOXICITY; EPIDERMAL GROWTH FACTOR RECEPTORS; GLIOBLASTOMAS; NEUTROPENIA; NEWLY DIAGNOSED GLIOBLASTOMA; ORGAN FUNCTIONS; PERFORMANCE STATUS; PHASE I; PHASE II; RADIATION RESISTANCE; TEMOZOLOMIDE; THERAPEUTIC BENEFITS; THROMBOCYTOPENIA; VANDETANIB; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

CHEMOTHERAPY; PEPTIDES; TOXICITY;

RADIOTHERAPY;

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; TEMOZOLOMIDE; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIVERTICULITIS; DRUG DOSE ESCALATION; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HUMAN; HYPERTENSION; LIVER FUNCTION TEST; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIVITY; RASH; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DIVERTICULITIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THROMBOCYTOPENIA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77955922743     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1741     Document Type: Article

References (58)

1. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
2. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 434 435
3. F.B. Furnari, T. Fenton, and R.M. Bachoo Malignant astrocytic glioma: Genetics, biology, and paths to treatment Genes Dev 21 2007 2683 2710
4. J.E. Chang, D. Khuntia, and H.I. Robins Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme Clin Adv Hematol Oncol 5 2007 894 902 907-815
5. B. Millauer, L.K. Shawver, and K.H. Plate Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant Nature 367 1994 576 579
6. K.H. Plate, G. Breier, and H.A. Weich Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo Nature 359 1992 845 848
7. J. Holash, P.C. Maisonpierre, and D. Compton Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 1999 1994 1998
8. T. Cloughesy, M.D. Prados, and P.Y. Wen A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [Abstract] J Clin Oncol 26 2008 2010b
9. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon II Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729 (Pubitemid 350086473)
10. T.N. Kreisl, L. Kim, and K. Moore Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
11. T. Batchelor, A.G. Sorensen, and M. Ancukiewicz A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma [Abstract] J Clin Oncol 2007 25
12. C.G. Lee, M. Heijn, and E. di Tomaso Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions Cancer Res 60 2000 5565 5570
13. D. Citrin, C. Menard, and K. Camphausen Combining radiotherapy and angiogenesis inhibitors: Clinical trial design Int J Radiat Oncol Biol Phys 64 2006 15 25
14. D.G. Duda, R.K. Jain, and C.G. Willett Antiangiogenics: The potential role of integrating this novel treatment modality with chemoradiation for solid cancers J Clin Oncol 25 2007 4033 4042
15. L. Geng, E. Donnelly, and G. McMahon Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy Cancer Res 61 2001 2413 2419
16. F. Winkler, S. Kozin, and R. Tong Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563
17. R. Jain Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy Science 307 2005 58 62
18. D.H. Gorski, M.A. Beckett, and N.T. Jaskowiak Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation Cancer Res 59 1999 3374 3378
19. S.V. Kozin, Y. Boucher, and D.J. Hicklin Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts Cancer Res 61 2001 39 44
20. V. Damiano, D. Melisi, and C. Bianco Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma Clin Cancer Res 11 2005 5639 5644
21. M. Sandstrom, M. Johansson, and U. Andersson The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model Br J Cancer 91 2004 1174 1180
22. J.N. Rich, S. Sathornsumetee, and S.T. Keir ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors Clin Cancer Res 11 2005 8145 8157
23. M. Sandstrom, M. Johansson, and P. Bergstrom Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model J Neurooncol 88 2008 1 9
24. R.K. Jain Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy Science 307 2005 58 62
25. Q. Zhou, P. Guo, and J.M. Gallo Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide Clin Cancer Res 14 2008 1540 1549
26. A.J. Ekstrand, N. Sugawa, and C.D. James Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails Proc Natl Acad Sci USA 89 1992 4309 4313
27. L. Frederick, X.Y. Wang, and G. Eley Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas Cancer Res 60 2000 1383 1387
28. A. Chakravarti, A. Dicker, and M. Mehta The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: A review of preclinical and correlative clinical data Int J Radiat Oncol Biol Phys 58 2004 927 931
29. S. Krishnan, R.D. Rao, and C.D. James Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas Front Biosci 8 2003 e1 e13
30. S.R. Wedge, D.J. Ogilvie, and M. Dukes ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 2002 4645 4655
31. F. Carlomagno, D. Vitagliano, and T. Guida ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res 62 2002 7284 7290
32. K.J. Williams, B.A. Telfer, and S. Brave ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: Schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 2004 8587 8593
33. B. Frederick, D. Gustafson, and C. Bianco ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy Int J Radiat Oncol Biol Phys 64 2006 33 37
34. W.D. Brazelle, W. Shi, and D.W. Siemann VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy Int J Radiat Oncol Biol Phys 65 2006 836 841
35. L.C. Marras, W.H. Geerts, and J.R. Perry The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review Cancer 89 2000 640 646
36. D.R. MacDonald, T.L. Cascino, and S.C. Schold Jr. Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1990 1277 1280
37. P.Y. Wen, and S. Kesari Malignant gliomas in adults N Engl J Med 359 2008 492 507
38. D.A. Reardon, P.Y. Wen, and A. Desjardins Glioblastoma multiforme: An emerging paradigm of anti-VEGF therapy Expert Opin Biol Ther 8 2008 541 553
39. R. Stupp, M.E. Hegi, and M.R. Gilbert Chemoradiotherapy in malignant glioma: Standard of care and future directions J Clin Oncol 25 2007 4127 4136
40. S.M. Chang, K.R. Lamborn, and M. Malec Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme Int J Radiat Oncol Biol Phys 60 2004 353 357
41. C.D. Turner, S. Chi, and K.J. Marcus Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme J Neurooncol 82 2007 95 101
42. J. Drappatz, E.T. Wong, and D. Schiff A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme Int J Radiat Oncol Biol Phys 73 2009 222 227
43. A. Narayana, J.G. Golfinos, and I. Fischer Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma Int J Radiat Oncol Biol Phys 72 2008 383 389
44. F. Taguchi, Y. Koh, and F. Koizumi Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models Cancer Sci 95 2004 984 989
45. F. Ciardiello, R. Bianco, and R. Caputo Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy Clin Cancer Res 10 2004 784 793
46. A.M. Omuro, S. Faivre, and E. Raymond Lessons learned in the development of targeted therapy for malignant gliomas Mol Cancer Ther 6 2007 1909 1919
47. A. Chakravarti, B. Berkey, and H. Robins An update of phase II results from RTOG 0211: A phase I/II study of gefitinib with radiotherapy in newly diagnosed glioblastoma. [Abstract] J Clin Oncol 24 2006 1527
48. P.D. Brown, S. Krishnan, and J.N. Sarkaria Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177 J Clin Oncol 26 2008 5603 5609
49. M.D. Prados, S.M. Chang, and N. Butowski Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma J Clin Oncol 27 2009 579 584
50. S.N. Holden, S.G. Eckhardt, and R. Basser Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors Ann Oncol 16 2005 1391 1397
51. D. Lee Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer Clin Lung Cancer 7 2005 89 91
52. T.J. Semrad, R. O'Donnell, and T. Wun Epidemiology of venous thromboembolism in 9489 patients with malignant glioma J Neurosurg 106 2007 601 608
53. R. Simanek, R. Vormittag, and M. Hassler Venous thromboembolism and survival in patients with high-grade glioma Neuro-oncol 9 2007 89 95 (Pubitemid 46580310)
54. A.A. Brandes, E. Scelzi, and G. Salmistraro Incidence of risk of thromboembolism during treatment high-grade gliomas: A prospective study Eur J Cancer 33 1997 1592 1596
55. A.D. Norden, J. Drappatz, and A.S. Ciampa Colon perforation during antiangiogenic therapy for malignant glioma Neuro-oncol 11 2009 92 95
56. K.D. Miller, J.M. Trigo, and C. Wheeler A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer Clin Cancer Res 11 2005 3369 3376
57. E.T. Wong, and S. Brem Antiangiogenesis treatment for glioblastoma multiforme: Challenges and opportunities J Natl Compr Cancer Netw 6 2008 515 522
58. A. Lai, E. Filka, and B. McGibbon Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: Interim analysis of safety and tolerability Int J Radiat Oncol Biol Phys 71 2008 1372 1380